Simple Summary This HEMATO-MADRID COVID-19 study assessed COVID-19 outcomes in
1818 hematologic cancer patients from February 2020 to October 2022 across different …

Purpose: The objective of this study was to evaluate the potential risk factors associated with
severe infection and unfavorable outcomes among individuals with hematologic …

Simple Summary There are contradictory data about coronavirus disease (COVID-19) in
patients with hematological malignancies. In this population-based study we evaluated …

Patients with hematologic malignancies are often immunodeficient and therefore have a
higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We …

As the COVID‐19 variant Omicron surge in Beijing, China, a better understanding of risk
factors for adverse outcomes may improve clinical management in patients with …

Patients with hematologic malignancies have both an increased risk for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and higher morbidity/mortality …

The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due
to its high transmissibility, although it appears to be less pathogenic than previous strains …

Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

Background: Patients with hematologic malignancy (HM) are hypothesized to be at high risk
of poor outcomes with coronavirus disease 2019 (COVID-19), due to disease and therapy …